Issue of Equity

 

TIDMPYN 
 
RNS Number : 8927T 
Phynova Group PLC 
15 June 2009 
 

15 June 2009 
 
 
Phynova Group plc 
("the Company") 
 
 
Issue of Equity 
 
 
The Company announces that it has issued 194,206 new ordinary shares ("New 
Ordinary Shares") in the capital of the Company. 
 
 
Of the New Ordinary Shares, 50,000 shares are being subscribed for by an 
existing shareholder of the Company on the same terms as the recent placing, as 
announced on 1 May 2009. The remaining 144,206 shares are to be issued to a 
service provider in satisfaction of fees. 
 
 
Application has been made for the admission to trading on AIM of the New 
Ordinary Shares and dealings are expected to commence on 19 June 2009. Following 
the admission of these shares, the Company will have 31,716,726 ordinary shares 
in issue. 
 
 
For further information, please contact: 
 
 
+--------------------------------------------+----------------------------+ 
| Phynova Group PLC                          |        [phone] | 
+--------------------------------------------+----------------------------+ 
| Steve Harris (Non-Executive Chairman)      |                            | 
+--------------------------------------------+----------------------------+ 
| Robert Miller (Chief Executive Officer)    |                            | 
+--------------------------------------------+----------------------------+ 
|                                            |                            | 
+--------------------------------------------+----------------------------+ 
| Nominated Adviser and Broker:              |                            | 
+--------------------------------------------+----------------------------+ 
| John East & Partners Limited               |       [phone] | 
+--------------------------------------------+----------------------------+ 
| John East/Simon Clements                   |                            | 
+--------------------------------------------+----------------------------+ 
|                                            |                            | 
+--------------------------------------------+----------------------------+ 
 
 
 
 
Notes to Editors: 
 
 
About Phynova 
Phynova is a UK company developing new prescription pharmaceuticals derived from 
plants used in Chinese medicines. The Company is focused on viral and bacterial 
diseases, metabolic diseases and cancer. Phynova's lead product for hepatitis C 
has now completed a Phase I/II trial in the US. One further product, for 
post-operative ileus, is targeted for entry to the clinic and there are a 
further four products in preclinical development. 
 
 
For further information please visit www.phynova.com. 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 IOECKPKBKBKDPAD